A long-term latent reservoir for HIV-1: discovery and clinical implications
- PMID: 15163657
- DOI: 10.1093/jac/dkh292
A long-term latent reservoir for HIV-1: discovery and clinical implications
Abstract
Despite the remarkable success of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection, it now appears that the infection is intrinsically incurable with antiretroviral therapy alone. The major reason is that the virus can persist in a latent form in resting memory CD4 cells. These cells arise when infected CD4+ lymphoblasts carrying an integrated copy of the HIV-1 genome revert back to a resting memory state. In this resting state, CD4 cells are minimally permissive for virus gene expression, and infected memory cells can survive for many years. Following re-exposure to the relevant antigen or other activating stimuli, these cells can begin to produce virus again. The existence of a stable reservoir has altered treatment strategies in several ways. HAART is no longer given with the goal of eradication. In addition, the reservoir serves as a permanent archive for wild-type virus and for drug-resistant variants that arise during treatment. Thus, once resistance to a particular drug arises, the patient will always carry that resistance. Interruption in treatment results in the re-emergence of the original wild-type virus, which often replicates better than drug-resistant virus. Although HAART cannot eradicate the infection, current regimens do come close to stopping virus evolution. Free viruses found in the plasma at low levels in patients on HAART resemble viruses in the latent reservoir and do not contain new drug resistance mutations. Thus although HAART cannot produce eradication, lifetime control of the infection with antiretroviral drugs may be possible.
Similar articles
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.J Virol. 2002 Sep;76(18):9481-92. doi: 10.1128/jvi.76.18.9481-9492.2002. J Virol. 2002. PMID: 12186930 Free PMC article.
-
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.J Virol. 2005 Apr;79(8):5185-202. doi: 10.1128/JVI.79.8.5185-5202.2005. J Virol. 2005. PMID: 15795302 Free PMC article.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
A reservoir for HIV in patients on combination antiretroviral therapy.Hopkins HIV Rep. 1998 Jan;10(1):1, 5-6, 11. Hopkins HIV Rep. 1998. PMID: 11365130
Cited by
-
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12. Antimicrob Agents Chemother. 2013. PMID: 23403426 Free PMC article.
-
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.PLoS Comput Biol. 2009 Oct;5(10):e1000533. doi: 10.1371/journal.pcbi.1000533. Epub 2009 Oct 16. PLoS Comput Biol. 2009. PMID: 19834532 Free PMC article.
-
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.Antimicrob Agents Chemother. 2010 Aug;54(8):3460-70. doi: 10.1128/AAC.01766-09. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439612 Free PMC article.
-
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.Antimicrob Agents Chemother. 2005 Jul;49(7):2657-64. doi: 10.1128/AAC.49.7.2657-2664.2005. Antimicrob Agents Chemother. 2005. PMID: 15980333 Free PMC article.
-
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3879-84. doi: 10.1073/pnas.0800050105. Epub 2008 Mar 10. Proc Natl Acad Sci U S A. 2008. PMID: 18332425 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials